Mice were immunized with synthetic peptides covering the first 56 amino acids of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) and a fusion protein, produced in Escheriehia coli, containing the first 55 amino acid residues of gD. It was found that mice immunized with peptides composed of amino acid residues 1 to 13, 18 to 30, 22 to 38 and 38 to 56 ofgD were not significantly protected against a lethal challenge with HSV-1. Immunization with peptide 9-21 and the gD fusion protein resulted in significant protection. Antisera, from mice immunized with HSV-I, were investigated for reactivity with a series of 57 overlapping gD peptides covering the entire amino acid sequence, except for the membrane-spanning region. All antisera reacted with peptides 9-21, 10-24, 151-165, 216-232, 282-301 and with peptide 340-354 located in the anchoring region of gD, and 15 other peptides were recognized by at least one antiserum. Twelve peptides (10-24, 151-165, 216-232, 244-267, 260-274, 270-284, 260-284, 282-301,300-314, 340-354, 348-362 and 355-369) reacted most frequently with the hyperimmune sera from mice and were selected for further study. These were conjugated to bovine serum albumin and used to immunize rabbits. Only antisera against peptide 10-24, which covers the same epitope as peptide 9-21, neutralized HSV-1 in vitro.
Introduction
Herpes simplex viruses (HSV) are the causative agents of a number of human diseases, such as localized skin infections of the oral, ocular and genital regions. They are often responsible for disseminated infections in immunocompromised hosts. Facial infections are usually associated with serotype HSV-1, whereas serotype HSV-2 mainly causes genital infections. The virus envelope carries a number of glycoproteins one of which is glycoprotein D (gD). Immunity against gD, obtained either by transfer of monoclonal antibodies against this glycoprotein or by immunization with gD, interferes with the infection process (Chan, 1983; Hall & Katrak, 1986; Long et al., 1984; Rector et al., 1982) . Furthermore, there is evidence that gD plays a role in the early stages of the infection process. Potent virus-neutralizing monoclonal antibodies against gD were unable to block the attachment of HSV virions to ceils, but inhibited the penetration of the nucleocapsid into the cells (Fuller & Spear, 1985) . HSV virions lacking gD were able to attach to cells but did not penetrate (Johnson & Ligas, 1988;  Present address: Eurosequence BV, Nijenborgh 16, 9747 AG Groningen, the Netherlands. 0000-9356 © 1990 SGM Johnson & Spear, 1989) . For these reasons, gD has received a great deal of attention as a component in a potential HSV vaccine.
The genes encoding gD of HSV-1, and also HSV-2, have been localized and sequenced (Lasky & Dowbenko, 1984; Watson, 1983 ; Watson et al., 1982) , and the amino acid sequences of the glycoproteins show a high degree of similarity. Studies in which the binding properties of anti-gD monoclonal antibodies with both types of gD were investigated show that gD-1 and gD-2 have common epitopes. One of these epitopes, which reacts with group VII monoclonal antibodies, is located in the N-terminal region of gD (Bosch et al., 1987; Cohen et al., 1984; Dietzschold et al., 1984; Eisenberg et al., 1985a) . Synthetic peptides, composed of amino acid residues 1 to 23 and 8 to 23 of mature gD-1, stimulated the production of antibodies that neutralized HSV-1 and HSV-2 infectivity in vitro . Mice immunized with these peptides were protected against a lethal challenge with HSV-2 (Eisenberg et al., 1985b) . In another study, HSV-I neutralizing antibodies were generated by peptides comprising residues 2 to 21 and 12 to 21 of HSV-1 gD (Strynadka et al., 1988) . Weijer et al. (1988) investigated the HSV-1 neutralizing activities of antisera directed against 11 synthetic peptides from nine separate regions of the amino acid sequence of gD-1. Immunization with the N-terminal peptides, especially peptide 9-21 and multiple repeats of this peptide, stimulated the production of virus-neutralizing antibodies (van der Ploeg et al., 1989) and elicited a delayed type hypersensitivity response to HSV (Geerligs et at., 1989) . Antibodies against this peptide strongly reacted with gD-1 in an immunoblot test.
A larger fragment of gD, produced as a fusion protein consisting of//-galactosidase and the first 55 amino acid residues of gD-1 in Escherichia coli (gD fusion protein), also stimulated the production of HSV-1 neutralizing antibodies (Kocken et al., 1988) . The antisera directed against this fusion protein were investigated for reactivity with a series of peptides covering the N-terminal region of gD. The antisera strongly reacted with a peptide, composed of residues 38 to 56, whereas a relatively weak reaction with peptide 9-21 was observed. The results of Kocken et al. (1988) suggest that the N terminus of gD may contain additional antigenic regions, other than the one covered by peptide 9-21. To obtain information on the presence of different neutralizing epitopes in the N-terminal part of gD, mice were immunized with the gD fusion protein or peptides 1-13, 9-21, 18-30, 22-38 and 38-56 , and subsequently challenged with a lethal dose of HSV-1.
In order to locate antigenic parts of gD, the antisera from the mice of the control group, which had been immunized with inactivated HSV-1 and survived the challenge, were investigated for reactivity with a series of overlapping synthetic peptides of gD. In earlier reports Strynadka et al., 1988) , a limited number of synthetic gD peptides were used in antigenicity studies. The peptides used in the former studies were selected using prediction algorithms. In the present study, which is an extension of the previous reports, the entire amino acid sequence of gD, except for the membrane-spanning region~ was synthesized as overlapping peptides. These peptides were tested for reactivity with anti-HSV-1 antisera.
Those overlapping peptides which were recognized most frequently by the antisera were selected, and used to immunize rabbits. The rabbit antisera were tested for their capability to neutralize HSV-1 infectivity in vitro.
Methods
Cells and virus. Vero cells were grown in medium 199 supplemented with 10% newborn calf serum and antibiotics. Monolayers were infected with HSV-1, strain McIntyre. Inactivated virus was prepared by infection of cells at a multiplicity of 0.1. After 4 days, extracellular virus was isolated and heat-inactivated for 30 min at 56 °C, and stored at -80 °C. Infectious virus (for challenge experiments) was prepared by infecting cells at a multiplicity of 10. Medium was removed 18 h after infection, and the cells were scraped into a small volume. Cells were sonicated and debris was removed by low-speed centrifugation. The supernatant was stored at -80 °C. The number of infectious virus particles was determined by a plaque assay . Briefly, virus dilutions were plated on monolayers of Vero cells in six-well trays. Overlay medium containing 0-5% methyl cellulose was added. After 3 days, the monolayers were fixed and subsequently stained with Giemsa. Plaques were counted and the titres expressed as p.f.u, per ml.
Peptides. Peptides, composed of amino acid residues 1 to 13, 9 to 2i, 18 to 30, 22 to 38, 31 to 46, 38 to 56, 57 to 77, 78 to 98, 82 to93, 99 to 117, 118 to 137, 137 to 150, 151 to 165, 166 to 180, 181 to 197, 198 to 215, 216 to 232, 232 to 243,244 to 267,260 to 284, 267 to 281,282 to 301 and 302 to 315 of gD-1, were synthesized by solid-phase methods (Barany & Merrifield, 1980) , desalted and purified as described previously . Amino acid compositions were verified by amino acid analyses. Peptides, comprising amino acid residues 1 to 14, 10 to 24, 20 to 34, 30 to 44, 40 to 54, 50 to 64, 60 to 74, 70 to 84, 80 to 94, 90 to 104, 100to 114, ll0to 124, 120to 134, 130to 144, 140to 154, 150to 164, 160 to 174, 170 to 184, 180 to 194, 190 to 204, 200 to 214, 210 to 224, 220 to 234, 230 to 244,240 to 254, 250 to 264, 260 to 274, 270 to 284, 280 to 294, 290 to 304, 300 to 314, 340 to 354, 348 to 362 and 355 to 369 of gD-1, were synthesized by the method of Houghten (Houghten, 1985) . To avoid side-chain reactions and aggregation of peptides, methionine and cysteine were substituted by norleucine and alanine, respectively. Norleucine has the same overall shape as methionine (Barany & Merrifield, 1980) and, of all possible alternative amino acids, alanine has the most similar overall shape as cysteine. This substitution was also applied in other studies (Arnon et aL, 1974; Jacob et al., 1983) . The peptides were desalted and the N-terminal amino acid was determined by dansylation (Wootton et aL, 1975) . Analysis of the peptides by reversed-phase HPLC at 214 nm , showed an average purity of 80 to 90%. The peptides composed of amino acid residues 1 to 13 and 1 to 14, were elongated N-terminally with a glycine. These peptides were designated peptide Gl-13 and peptide Gl-14, respectively.
Five synthetic peptides, G1 13, 9-21, 18-30, 22-38 and 38 56, were used for immunization of mice. As a negative control in the immunization of mice, we used a peptide consisting of amino acid residues 278 to 293 of the haemagglutinin-neuraminidase (HN) protein of Sendai virus (Blumberg et al., 1985) . Eight peptides, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 151 165, [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] 244 267, [260] [261] [262] [263] [264] [265] [266] [267] [268] [269] [270] [271] [272] [273] [274] [270] [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] [310] [311] [312] [313] [314] [340] [341] [342] [343] [344] [345] [346] [347] [348] [349] [350] [351] [352] [353] [354] , were used to immunize rabbits. The peptides were coupled to ovalbumin (OA) for immunization of mice, or to bovine serum albumin (BSA) for immunization of rabbits. The peptides were coupled by glutaraldehyde as described . The amount of coupled peptide was determined by amino acid analysis. The molar peptide/carrier protein ratios ranged from 2.4 to 3-5 for the peptide-OA conjugates, and from 3.5 to 6.3 for the peptide-BSA conjugates, with the exception of the conjugate of peptide 340-354 coupled to BSA, for which a peptide/carrier protein ratio of 1-0 was determined.
gDfusion protein. The gD fusion protein was prepared as described (Kocken et al., 1988) . Briefly, the sequence encoding a fragment composed of the N-terminal 55 amino acids of mature gD and the five C-terminal amino acids of the signal peptide, was cloned in the expression vector pEX3 and produced in E. coli as a cro-lacl-lacZ-gD (-5-55) fusion protein. Bacterial cells were lysed, and the insoluble protein fraction was collected and solubilized by boiling in 5~ SDS. Further purification was achieved by size-exclusion (SE) HPLC. Pure fractions of the fusion protein were used for immunization of mice. As a control, mice were immunized with the fusion protein lacking the gD fragment.
Injection of mice and rabbits. Groups of female BALB/c mice, 8 to 10 weeks of age, were immunized four times, at 3-week intervals, with 50 Mg of coupled peptide per injection, 20 Mg of the fusion proteins per injection or 2.5 x 106 p.f.u, of heat-inactivated HSV-1 per injection. Freund's complete adjuvant was used in the first injection, incomplete in the second and AI(OH)3 in the following injections. Injections were given intraperitoneally (i.p.). Seven days after the last injection, the mice were challenged i.p. with a lethal dose of 1-1 x 108 or 3.2 x 109 p.f.u. HSV-1 per animal.
Rabbits (Groot Chinchilla, 6 months old, two rabbits per peptide) were immunized subcutaneously with 100 ~tg of coupled peptide per injection, according to the same schedule as was used for immunization of the mice. Blood was collected 1 week after the fourth injection and serum samples were stored at -20 °C. The antisera were tested for their capability to neutralize HSV-I infectivity in vitro.
Neutralization of HSV-1 in vitro. The rabbit anti-peptide antisera were tested for neutralization of HSV-1 in a 50% plaque reduction assay. The assay was performed as described .
ELISA. Mice immunized with heat-inactivated HSV-I which survived subsequent challenge with 1.1 × 108 p.f.u. HSV-1, were bled after 48 days. Serum samples were tested, at a dilution of 1:99, in an ELISA for reactivity with a series of peptides of HSV-1 gD. Antipeptide antibody titres in sera from rabbits were determined using twofold serial dilutions. The ELISA was carried out as described . ELISA plates were coated with free peptides (1 ~tg per well) in 50mM-sodium carbonate-bicarbonate pH9.6, supplemented with 0.6M-NaC1. Peptides 267-281 and 24~267 were coated in 50 raM-sodium citrate pH 4.6, supplemented with 0.6 M-NaC1, and 50 mM-sodium phosphate pH 7.6, supplemented with 0.6 M-NaC1, respectively, because these peptides failed to coat the plates at pH 9.6 . The antisera, peroxidaselabelled anti-mouse IgG or peroxidase-labelled anti-rabbit lgG, were diluted in phosphate-buffered saline supplemented with 0.5 M-NaCI, 0.3% Tween 20 and 5% newborn calf serum. Reactions were considered as positive when A492 values were higher than 0.2.
Statistical analyses. Significance of differences in survival numbers
between groups of mice was analysed with a Chi-square test with continuity correction. P values lower than 0-05 were considered to be significant.
Results

Protection against a lethal HSV-1 challenge by immunization with gD peptides
Groups of BALB/c mice were immunized with peptidecarrier conjugates, and with the fusion protein with or without the gD fragment. Subsequently, the mice were challenged with two different doses of HSV-1. Table 1 summarizes the results of these experiments. In one experiment, mice were challenged with 1-1 x 108 p.f.u. per mouse. Of a control group of seven mice immunized with the fusion protein lacking the gD fragment, five died after the challenge. Ten mice were immunized with the gD fusion protein and, of this group, three animals died after the challenge. In contrast to this, the animals immunized with peptide 9-21 all survived the challenge. Using the peptides Gl-13 and 18-30, respectively, two other groups of mice were immunized. Of nine mice immunized with peptide G 1-13, five survived and six of the 10 mice immunized with peptide 18-30 also survived. The control group of 10 mice immunized with heatinactivated HSV-1 survived the challenge. The difference in survival numbers between the group immunized with the fusion protein lacking the gD fragment and the groups immunized with peptide 9-21 or inactivated HSV-1 was statistically significant. In another experiment, mice were challenged with 3-2 × l0 q p.f.u, of HSV-I per animal. Results obtained with peptide 9-21 and two additional gD peptides, 22-38 and 38-56, were compared with those obtained with a control peptide composed of amino acid residues 278 to 293 of Sendal virus HN protein (Table 1 ). All animals, immunized with either the Sendal virus peptide or peptides 22-38 and 38-56, died after the challenge. In contrast to this, 13 of 14 animals immunized with peptide 9-21 survived. The difference in survival numbers between this group and the groups immunized with either peptide 22-38 or 38-56 or the Sendal virus peptide was statistically significant.
Two groups, consisting of seven and five animals, were immunized with the fusion proteins, with and without the gD fragment, respectively. For the first and second injection the same amount of protein (20 Ixg per injection) was used as in the experiment described above~ but in the third injection 400 ~tg of protein not purified by SE-HPLC was used. All five mice immunized with the fusion protein without the gD fragment died within 7 days after the challenge, whereas all seven mice immunized with the gD fusion protein survived (Table  1) . The difference in survival numbers between both groups was statistically significant.
H. J. Geerligs and others
Reactivity of hyperimmune sera from mice with synthetic peptides of gD
Ten mice that had been immunized with heat-inactivated HSV-1 and survived challenge with 1.1 × l0 s p.f.u. HSV-1 were bled 48 days after the challenge. The reactivity of these antisera with a series of 57 overlapping gD peptides was investigated in an ELISA. The sera were used in a 100-fold dilution. As a control, sera derived from non-immune mice were tested for reactivity with the peptides. The latter sera did not react with any of the peptides. The results are summarized in Fig. 1 .
Thirty-six peptides were not recognized by any of the hyperimmune sera whereas six peptides, 9-21, 10-24, 151-165, 216-232, 282-301 and 340-354, were recognized by all 10 sera. The other 15 peptides were recognized by at least one antiserum.
One serum (M10) reacted with peptide 20-34 which overlaps peptides 9-21 and 10-24. A small number of sera reacted with peptides 90-104 (M7 and M10), 99-117 (M2 and M10), 118-137 (M2, M4 and M10) and 120-134 (M1, M2 and M10). Of these peptides three, 90-104, 118-137 and 120-134 (Fig. 1) , contain potential glycosylation sites. Peptide 150-164 overlaps peptide 151-165 and was recognized by one serum (M4). An important antigenic region might be located between residues 244 and 301. Several sera reacted with eight peptides located within this region, peptides 244-267 (all, except M1 and M5), 250-264 (M4), 260-274 (M10), 260-284 (M1, M2, M3, M7 and M8), 267-281 (M8), 270-284 (M5 and M8), 280-294 (M5) and 282-301 (all sera). Of these peptides, four, 244-267, 250-264, 260-274 and 260-284 (Fig. 1) , contain a potential glycosylation site. Another important antigenic region might be located in the cytoplasmic anchor region. Peptide 348-362 was recognized by nine antisera (all, except M10) and peptide 355-369 by two antisera (M4 and M 10), whereas all antisera reacted with peptide 340-354.
As indicated above, 36 peptides were not recognized by any of the antisera. These were peptides G 1-13, G 1-14 and 18-30, all peptides located between residues 22 and 98, peptides 100-114, 110-124, 130-144, 137-150 and 140-154, the peptides located between residues 160 and 224, peptides 220-234, 230-244, 232-243 and 240-254, and the peptides located between residues 290 and 315.
Neutralization of HSV-1 by rabbit anti-peptide antisera
Of the peptides that showed a positive reaction with the mouse anti-HSV-1 antisera, 12 were investigated for their capacity to elicit HSV-neutralizing antibodies. These peptides (10-24, 151-165, 216-232, 244-267, 260-274, 270-284, 260-284, 282-301,300-314, 340-354, 348-362 and 355-369) were coupled to BSA and the conjugates were used to immunize rabbits. BSA was used because this carrier protein appeared to be relatively successful in the generation of high anti-peptide antibody titres in rabbits . [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] 80 94, [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] 140 154", 160 174, [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] 200 214", [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] 260 274, [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] [310] [311] [312] [313] [314] [340] [341] [342] [343] [344] [345] [346] [347] [348] [349] [350] [351] [352] [353] [354] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] 110 124", [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] 170 184, [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] 230 244, [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] [270] [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 82 93, [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [267] [268] [269] [270] [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] 2~38, 38 56, 57 77*, [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] . Line 5: peptides 31-46 and 260 284. *, Peptides in which methionine at positions 11, 102, 113, 153, 219 and 315 was substituted by norleucine and/or cysteine at positions 66, 106, 118, 127, 189 and 202 was substituted by alanine. The peptides were tested for reactivity with 10 antisera derived from mice that had been immunized with heat-inactivated HSV-1 and survived subsequent challenge with HSV-1. The antisera were used in a 100-fold dilution in the ELISA. I I, peptides not reacting with antisera; kN--N-~, peptides reacting with one to five of the antisera; I~, peptides reacting with six to nine of the antisera; ~, peptides reacting with all 10 antisera. * Peptides were coupled to BSA prior to immunization. t Anti-peptide antibody titres were determined by ELISA, using the homologous peptide for coating the plates. :~ Neutralization titres were determined in a 50~ plaque reduction assay.
peptide antibody titres were determined in an ELISA and a 50~ plaque reduction assay was performed to determine HSV-1-neutralizing antibodies. Table 2 shows that all peptide-carrier protein conjugates elicited detectable anti-peptide antibodies. Highest titres were found after immunization with a conjugate of peptide 10-24: Relatively low titres were found for the peptides 151-165, 282-301 and 260-284. The results obtained in the plaque reduction assay show that only the antisera obtained after immunization with peptide 10-24 neutralized HSV-1, whereas the other anti-peptide antisera did not.
Discussion
Significant protection against a lethal dose of HSV-1 was achieved after immunization with the gD fusion protein and the synthetic peptide comprising residues 9 to 21 of gD (Geerligs et al., 1989; van der Ploeg et al., 1989) . The other four peptides from the N-terminal region did not confer significant protection. Kocken et al. (1988) found that immunization with the gD fusion protein resulted in the production of potent virus-neutralizing antibodies. These antibodies strongly reacted with peptide 38-56 (Kocken et al., 1988) . Our results show that immunization with this peptide did not confer protection against HSV-1 in vivo. Peptide 38-56 probably represents an immunogenic domain of the gD fusion protein rather than a virus-neutralizing epitope.
In immunization studies by others, the potential of synthetic peptides to confer resistance to HSV-2 was demonstrated. Although there is a high degree of amino acid sequence similarity between gD-1 and gD-2, there are some differences with regard to infections caused by HSV-1 and HSV-2 in mice. After i.p. inoculation, HSV-2 infections cause hepatitis whereas HSV-1 does not. Both types of HSV cause infections in the central nervous system, but the entry of HSV-2 into that system is slower than that of HSV-1 (Renis et al., 1976) . Eisenberg et al., (1985 b) found that immunization of mice with synthetic peptides 1-23 and 8-23 of gD-1 coupled to keyhole limpet haemocyanin conferred resistance against infection by HSV-2. In that study, mice were injected four times with the peptide-carrier conjugates. Watari et al. (1987) immunized mice with a single dose of peptide 1-23 of gD-I exposed on liposomes and emulsified in Freund's complete adjuvant. These mice were protected significantly against a challenge with HSV-2.
Antigenic regions of gD have been investigated by determining the reactivity of polyclonal antisera to HSV and monoclonal antibodies against gD, with synthetic peptides and with internal deletion mutants of gD. The monoclonal antibodies have been classified into groups (Eisenberg et al., 1982) . Of the groups, four (II, V, VII and XI) define continuous epitopes (Eisenberg et al., 1985 a; Isola et al., 1989) and four other groups (I, III, IV and VI) recognize conformation-dependent epitopes (Cohen et al., 1986; Muggeridge et al., 1988; Minson et al., 1986) . Two groups of monoclonal antibodies (IX and X) did not correspond to any of the existing epitopes and, in addition, unclassified monoclonal antibodies have been described (Minson et al., 1986; Highlander et al., 1987) . Group VIII monoclonal antibodies are HSV-2-specific (Eisenberg et al., 1982; Rawls et al., 1984) .
A series of overlapping peptides, covering the entire amino acid sequence except for the membrane-spanning region, was used to determine the linear regions of gD which were recognized by sera from mice that were immunized and subsequently challenged with HSV-1. All the antisera from the 10 mice reacted with peptides 9-21, 10-24, 151-165, 216-232, 282-301 and 340-354 . The peptides 9-21 and 10-24 correspond to the epitope of group VII monoclonal antibodies, which is located between residues 9 and 20 (Eisenberg et al., 1985a ). An antigenic region of gD in which residues 151 to 165 are involved has not yet been described and may contribute to conformational epitopes for monoclonal antibodies of the groups III, IV and VI, which are located between residues 1 and 226 (Cohen et al., 1986) . In peptide 216-232, residue 216 is present; this residue has been shown to be involved in the reaction with the group IA monoclonal antibody LP2 (Minson et al., 1987; Muggeridge et al., 1988) . This peptide, or part of it, may be involved in the conformation-dependent epitope recognized by group I monoclonal antibodies, which is partly located between residues 233 and 259 (Muggeridge et al., 1988; Cohen et al., 1986) . Peptide 282-301 corresponds to the epitope of group XI monoclonal antibodies, which is located between residues 284 and 301 (Isola et al., 1989) . Peptide 340-354 reacted with all 10 mice sera. This peptide is located in the C terminus of the gD molecule and corresponds to the epitope of group V monoclonal antibodies, which is located between residues 340 and 356 (Eisenberg et al., 1985a) . The positive reaction of a number of the antisera with the other two peptides in the C-terminal region suggests that a large linear antigenic region is present in this part of the molecule.
In the region comprising residues 90 to 137, four of the six peptides synthesized reacted with at least one of the antisera. These peptides might represent sequential regions of yet to be identified epitopes. The six peptides located between residues 244 and 284 were each recognized by at least one antiserum. These peptides may be either parts of the epitope recognized by group I monoclonal antibodies (partly located between residues 233 and 259) (Muggeridge et al., 1988; Cohen et al., 1986) , or may belong to the epitope defined by group II monoclonal antibodies, which is located between residues 264 and 279 (Eisenberg et al., 1985a; Isola et al., 1989) .
In two other studies, the antigenicity of synthetic peptides of gD was assessed by using polyclonal antisera raised in rabbits against gD (Isola et al., 1989) and convalescent sera of HSV patients (Strynadka et al., 1988) . At least eight of the nine rabbit anti-gD antisera (Isola et al., 1989) reacted with a number of peptides corresponding to antigenic regions that also reacted with the anti-HSV antisera from the mice in our study, i.e. the N-terminal region, the region composed of residues 264 to 301 and the C-terminal part, residues 340 to 369. Some of the rabbit sera reacted with peptides covering residues 77 to 98 and 303 to 312, but peptides of these regions did not react with the sera from the mice. The latter sera reacted with peptides from between residues 99 to 205 and residues 227 to 267, whereas rabbit sera did not. Peptide 216-232, which was reactive with the antisera from mice, partly overlaps peptides within the region of residues 206 to 226, which reacted with sera from the rabbits.
The convalescent sera of HSV patients (Strynadka et al., 1988) reacted with peptides in the N terminus of the molecule, peptides 52-61, 150-159, and 267-276. Peptides corresponding to the C-terminal region were not investigated with the human anti-HSV sera. Sera from humans, mice and rabbits all recognized the peptides of the N-terminal region up to residue 30 and peptides covering the region of residues 260 to 280, suggesting that these are immunodominant parts of the gD molecule with respect to sequential antigenic sites. Differences found in the reactivity of the antisera from the different species with the peptides may be the result of speciesdependent variation in the immune response, the use of peptides slightly different from each other in the three studies or differences in the way antisera were induced in the different animal species, i.e. HSV infection in humans (Strynadka et al., 1988) , immunization of rabbits with gD-1 or gD-2 (Isola et al., 1989) and immunization of mice with inactivated HSV-1, followed by infection with HSV-1 (the present study).
The peptides which reacted frequently with the anti-HSV antisera from the mice were selected to be used for immunization of rabbits. All peptides elicited antipeptide antibodies and the highest anti-peptide antibody titres were generated by peptide 10 24. Only peptide 10-24, of the 12 tested, elicited antibodies that were able to neutralize HSV-1 infectivity. Previous studies (Weijer et aI., 1988; Strynadka et aI., 1988; Watari et al., 1987; Eisenberg et al., 1985b; Cohen et al., 1984) , and also the present study, show that this peptide contains a region that elicits virus-neutralizing activity in vitro and in vivo. These results agree with those found by ; they found that only antisera against peptides covering the N-terminal region, especially peptide 9-21, neutralized viral infectivity. Furthermore, Eisenberg et al., 1985a) showed that antisera against peptides comprising residues 268 to 287 and 340 to 356, did not neutralize viral infectivity. Strynadka et al. (1988) found that antisera against peptides composed of residues 267 to 276 and 288 to 297 showed virus-neutralizing activity. These peptides overlap peptides 260-274, 270-284, 260-284 and 282-301, described in this study, which did not elicit virus-neutralizing antibodies. One of the reasons for this difference may be that additional amino acids at the C terminus or N terminus of a particular peptide may affect the conformation of this peptide resulting in a different antibody response.
